LONZA GROUP UNSP.ADR 1/10 Total Liabilities

Latest as of December 2025: €9.94 Billion EUR ≈ $11.62 Billion USD

LONZA GROUP UNSP.ADR 1/10 total liabilities. Based on the latest financial reports, LONZA GROUP UNSP.ADR 1/10 (LO3A) has total liabilities worth €9.94 Billion EUR (≈ $11.62 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LO3A defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Total Liabilities of LONZA GROUP UNSP.ADR 1/10 (2022–2025)

Total liabilities of LONZA GROUP UNSP.ADR 1/10 from 2022 to 2025. This chart illustrates how LONZA GROUP UNSP.ADR 1/10's total liabilities have evolved over time, based on quarterly financial data. Check LONZA GROUP UNSP.ADR 1/10 liquid asset ratio to evaluate the company's liquid asset resilience ratio.

LONZA GROUP UNSP.ADR 1/10 Competitors by Total Liabilities

The table below lists competitors of LONZA GROUP UNSP.ADR 1/10 ranked by their total liabilities.

Company Country Total Liabilities
Mercedes-Benz Group AG
F:MBG
Germany €161.23 Billion
Toyota Tsusho Corp
NYSE:TYHOY
USA $4.73 Trillion
RECRUIT HLD.UNSP.ADR/02
F:1RHA
Germany €1.14 Trillion
Yum! Brands Inc
NYSE:YUM
USA $15.49 Billion
Orange S.A.
PA:ORA
France €91.25 Billion
IDEXX Laboratories Inc
NASDAQ:IDXX
USA $1.83 Billion
Ameriprise Financial Inc
NYSE:AMP
USA $178.24 Billion
Kroger Company
NYSE:KR
USA $44.01 Billion

Liability Composition Analysis (2022–2025)

This chart breaks down LONZA GROUP UNSP.ADR 1/10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LO3A total asset value.

Liquidity & Leverage Metrics

LONZA GROUP UNSP.ADR 1/10 Total Liabilities Ratios Explained

LONZA GROUP UNSP.ADR 1/10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.56 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how LONZA GROUP UNSP.ADR 1/10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for LONZA GROUP UNSP.ADR 1/10 (2022–2025)

The table below shows the annual total liabilities of LONZA GROUP UNSP.ADR 1/10 from 2022 to 2025.

Year Total Liabilities Change
2025-12-31 €9.78 Billion
≈ $11.43 Billion
-5.46%
2024-12-31 €10.35 Billion
≈ $12.09 Billion
+41.02%
2023-12-31 €7.34 Billion
≈ $8.58 Billion
+9.64%
2022-12-31 €6.69 Billion
≈ $7.82 Billion
--

About LONZA GROUP UNSP.ADR 1/10

F:LO3A Germany Diagnostics & Research
Market Cap
$44.69 Billion
€38.23 Billion EUR
Market Cap Rank
#654 Global
#140 in Germany
Share Price
€54.50
Change (1 day)
+0.00%
52-Week Range
€49.60 - €63.50
All Time High
€72.95
About

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract develo… Read more